Expert guides, hospital insights, and medical travel tips for your China health journey
China has developed six domestically approved surgical robot platforms to challenge da Vinci's dominance. Here is what the clinical evidence shows — and why cost matters for international patients.
China is digitizing pathology at scale. AI systems evaluated at Chinese cancer centers are matching specialist pathologist performance in several cancer types — with implications for diagnostic access.
From trial volumes to published research output and regulatory milestones, here is a data-driven assessment of where China stands in the global stem cell research landscape.
China is using AI to decode the pharmacology of traditional herbal medicine, standardize TCM diagnosis, and bring evidence-based rigor to an ancient practice. The results are genuinely interesting.
Not all stem cell providers in China operate to the same standard. This guide gives patients a concrete due diligence framework for evaluating any Chinese stem cell hospital or clinic.
China's Precision Medicine Initiative and BGI's genomic sequencing network have created datasets that AI systems are translating into clinical insights. Here's what that means in practice.
China's stem cell clinical trials include significant programs targeting Type 1 diabetes, Type 2 diabetes complications, and liver cirrhosis. We review what the published data shows.
China's NMPA has approved over 280 AI medical imaging products. Here is how they are being used in hospitals — and what the real-world evidence shows about performance.
China has published some of the strongest clinical data globally on stem cell therapy for cartilage defects and knee osteoarthritis. Here's what the trials show and who is eligible.
In March 2025, Shanghai's Ruijin Hospital performed China's first GCP-standard iPSC cell transplant for Parkinson's disease. The 6-month results are published — here's an honest look.
China is now the world's second-largest hub for AI-driven drug discovery, with dozens of dedicated companies and multiple candidates in clinical trials. Here's what the pipeline looks like in 2025.
Anti-aging stem cell clinics are among the most aggressively marketed offerings in Asia. Here's what the evidence actually shows — and what patients should be cautious about.
Panda Touring Care Newsletter
Research-backed guides on stem cell therapy, hospital quality data, and medical travel — delivered weekly.
No spam, ever. Unsubscribe anytime.